CONTEXT AND OBJECTIVE: Estrogen receptor alpha (ER alpha), a potent transcription factor expressed in vascular endothelial cells, plays a key role in regulating vascular function and health. We determined whether vascular endothelial cell expression of ER alpha is influenced by estrogen status and is related to vascular endothelial function in healthy women. METHODS: ER alpha protein expression was measured (quantitative immunofluorescence) in endothelial cells from peripheral veins of 16 healthy, premenopausal women during the early follicular (EF) and late follicular (LF) phases of the menstrual cycle and 17 estrogen-deficient postmenopausal women. Endothelial-dependent dilation (EDD; brachial artery flow-mediated dilation) and endothelial nitric oxide synthase (eNOS) expression and activation were also measured in a subgroup of women. RESULTS: In premenopausal women (n = 10), ER alpha expression was 30% lower (P < 0.001) during the EF (low estrogen) compared with the LF (high estrogen) phase of the menstrual cycle. In postmenopausal women, ER alpha expression was 33% lower (P < 0.001) compared with the LF phase of the menstrual cycle in premenopausal women. ER alpha expression was strongly related (r = 0.67; P < 0.001) to EDD, which was reduced in postmenopausal women. ER alpha abundance was positively related to expression of eNOS (r = 0.54; P = 0.009; n = 21) and ser1177 phosphorylated eNOS (r = 0.59; P = 0.006; n = 20). CONCLUSIONS: These results provide the first evidence that expression of ER alpha in vascular endothelial cells is modulated by estrogen status and may be a key determinant of vascular endothelial function in healthy pre- and postmenopausal women. ER alpha expression may influence vascular endothelial function in women by affecting protein levels and activation of eNOS.
CONTEXT AND OBJECTIVE:Estrogen receptor alpha (ER alpha), a potent transcription factor expressed in vascular endothelial cells, plays a key role in regulating vascular function and health. We determined whether vascular endothelial cell expression of ER alpha is influenced by estrogen status and is related to vascular endothelial function in healthy women. METHODS:ER alpha protein expression was measured (quantitative immunofluorescence) in endothelial cells from peripheral veins of 16 healthy, premenopausal women during the early follicular (EF) and late follicular (LF) phases of the menstrual cycle and 17 estrogen-deficient postmenopausal women. Endothelial-dependent dilation (EDD; brachial artery flow-mediated dilation) and endothelial nitric oxide synthase (eNOS) expression and activation were also measured in a subgroup of women. RESULTS: In premenopausal women (n = 10), ER alpha expression was 30% lower (P < 0.001) during the EF (low estrogen) compared with the LF (high estrogen) phase of the menstrual cycle. In postmenopausal women, ER alpha expression was 33% lower (P < 0.001) compared with the LF phase of the menstrual cycle in premenopausal women. ER alpha expression was strongly related (r = 0.67; P < 0.001) to EDD, which was reduced in postmenopausal women. ER alpha abundance was positively related to expression of eNOS (r = 0.54; P = 0.009; n = 21) and ser1177 phosphorylated eNOS (r = 0.59; P = 0.006; n = 20). CONCLUSIONS: These results provide the first evidence that expression of ER alpha in vascular endothelial cells is modulated by estrogen status and may be a key determinant of vascular endothelial function in healthy pre- and postmenopausal women. ER alpha expression may influence vascular endothelial function in women by affecting protein levels and activation of eNOS.
Authors: Lori Mosca; Lawrence J Appel; Emelia J Benjamin; Kathy Berra; Nisha Chandra-Strobos; Rosalind P Fabunmi; Deborah Grady; Constance K Haan; Sharonne N Hayes; Debra R Judelson; Nora L Keenan; Patrick McBride; Suzanne Oparil; Pamela Ouyang; Mehmet C Oz; Michael E Mendelsohn; Richard C Pasternak; Vivian W Pinn; Rose Marie Robertson; Karin Schenck-Gustafsson; Cathy A Sila; Sidney C Smith; George Sopko; Anne L Taylor; Brian W Walsh; Nanette K Wenger; Christine L Williams Journal: Circulation Date: 2004-02-04 Impact factor: 29.690
Authors: Christopher E Ihionkhan; Ken L Chambliss; Linda L Gibson; Lisa D Hahner; Michael E Mendelsohn; Philip W Shaul Journal: Circ Res Date: 2002-11-01 Impact factor: 17.367
Authors: D S Celermajer; K E Sorensen; V M Gooch; D J Spiegelhalter; O I Miller; I D Sullivan; J K Lloyd; J E Deanfield Journal: Lancet Date: 1992-11-07 Impact factor: 79.321
Authors: Andrew V Kuczmarski; Leena N Shoemaker; Joshua C Hobson; David G Edwards; Megan M Wenner Journal: Am J Physiol Heart Circ Physiol Date: 2020-06-19 Impact factor: 4.733
Authors: Daniel P Credeur; Leryn J Reynolds; Seth W Holwerda; Jennifer R Vranish; Benjamin E Young; Jing Wang; John P Thyfault; Paul J Fadel Journal: Exp Physiol Date: 2018-02-14 Impact factor: 2.969
Authors: Yasina B Somani; James A Pawelczyk; Mary Jane De Souza; Penny M Kris-Etherton; David N Proctor Journal: Am J Physiol Heart Circ Physiol Date: 2019-06-07 Impact factor: 4.733
Authors: J Mikhail Kellawan; Rebecca E Johansson; John W Harrell; Joshua J Sebranek; Benjamin J Walker; Marlowe W Eldridge; William G Schrage Journal: Eur J Appl Physiol Date: 2015-03-28 Impact factor: 3.078
Authors: Megan M Wenner; Kelly N Sebzda; Andrew V Kuczmarski; Ryan T Pohlig; David G Edwards Journal: Am J Physiol Regul Integr Comp Physiol Date: 2017-04-24 Impact factor: 3.619
Authors: Areepan Sophonsritsuk; Susan E Appt; Thomas B Clarkson; Carol A Shively; Mark A Espeland; Thomas C Register Journal: Menopause Date: 2013-05 Impact factor: 2.953